PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

NHS adapts to pandemic with ‘COVID-friendly’ cancer treatments

NHS chief executive Sir Simon Stevens has announced plans for a £160m initiative to roll-out ‘COVID-friendly’ cancer treatments for patients across the UK.

The funding will be used to pay for treatments, which do not have as big an impact on patients’ immune systems and require less hospital visits compared to other drugs.

As some these new options require few or no hospital visits, patients are less susceptible to contracting the SARS-CoV-2 virus, which causes COVID-19, as well as other infections.

According to the NHS, thousands of cancer patients have already benefitted from around 50 treatments approved for use in place of existing drugs.

More treatments are expected to become available this week, after a number of new deals were struck between the NHS and pharma companies.

This includes targeted hormone therapies such as Astellas/Pfizer’s Xtandi (enzalutamide) for prostate cancer, Celgene’s myeloma treatment Revlimid (lenalidomide) and Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) for first-line bladder cancer.

“Since the first case of COVID in England six months ago, NHS staff have fast tracked new, innovative ways of working so that other services, including A&E, cancer and maternity could continue safely for patients and it is thanks to these incredible efforts that 65,000 people could start treatment for cancer during the pandemic,” said Stevens.

“We are now adopting new, kinder treatment options which are not only effective but safer for use during the COVID-19 pandemic and more convenient for thousands of patients, who can take medication at home or be given medicines with less harmful effects on their immune system,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026